Year-end Sale % OFF 
Abstract
Response: Commentary: Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model.
Highlights
This would not change the clear fact that we observed no significant differences between anti-PD-1 antibody- and IgG control-treated JNPL3 groups in cognition or related tauopathy markers
We compared the phenotype of JNPL3 tauopathy mice randomized to anti-PD-1 antibody and IgG control groups
We agree that including age-matched wild-type mice would have provided a useful reference for the magnitude of any deficits or improvements. This would not change the clear fact that we observed no significant differences between anti-PD-1 antibody- and IgG control-treated JNPL3 groups in cognition or related tauopathy markers
Summary
This would not change the clear fact that we observed no significant differences between anti-PD-1 antibody- and IgG control-treated JNPL3 groups in cognition or related tauopathy markers. Chronic PD-1 Blockade for Tauopathy middle-aged animals to better relate to the prior work of Rosenzweig et al (2019), starting the anti-PD-1 antibody treatment when the tauopathy mice have moderate to severe tau pathology.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
